Articles by Wenbiao Liu, MD
Synopsis of Angiogenesis Inhibitors in Oncology
ByLee M. Ellis, MD, FACS,Wenbiao Liu, MD,Fan Fan, MD,Young Do Jung, MD, PhD,Niels Reinmuth, MD,Oliver Stoeltzing, MD,Akihiko Takeda, MD,Morihisa Akagi, MD,Alexander A. Parikh, MD,Syed Ahmad, MD Angiogenesis is a dynamic process essential for primary tumor growth and metastases. New insights into the basic understanding of the biologic processes responsible for angiogenesis have led to the characterization of potential therapeutic targets. Several strategies for the development of antiangiogenic therapeutic modalities have been employed, including agents that (1) decrease the activity of specific angiogenic factors, (2) decrease the activity of endothelial survival factors, (3) increase the activity of naturally occurring antiangiogenic agents, or (4) indirectly downregulate angiogenic and survival factor activity.
Tumor angiogenesis is a complicated process that is regulated by numerous factors simultaneously and in a coordinated fashion.
Role of Angiogenesis Inhibitors in Cancer Treatment
ByLee M. Ellis, MD, FACS,Wenbiao Liu, MD,Niels Reinmuth, MD,Raymond M. Shaheen, MD,Young Do Jung, MD, PhD,Syed Ahmad, MD Angiogenesis is essential for the growth of both primary andmetastatic tumors. This process, more complex than was previously thought,
